Kuehne+Nagel’s Post

What does 2024 hold for biopharma? Eleanor Malone of Scrip Citeline Commercial features industry vanguards, including our Co-Founder and CTO Gevorg Grigoryan. Gevorg elucidates the pivotal role of #AI in revolutionizing biopharma, underscoring our leadership in driving these innovations.    In the article, Gevorg predicts that “soon we will see new drugs entering the clinic that have been completely computer-generated. Those medicines will transform the entire value chain from lab, to clinic, to regulatory approval, to the patient’s bedside. #MachineLearning has brought us to the brink of this revolution – we anticipate seeing the first clinical proofs of concept in 2024.”    Read more insights on the transformative technologies shaping the future of biopharma: https://lnkd.in/dWeM2Bcy    #ProteinEngineering I #GenerativeAI 

Future of Genetics..!

Meet the Tenthpin Supply Chain Experts at the LogiPharma in Lyon, France next week. Patrick Wolf, Stephanie Marx, Alexander Blount and João Valério will be there from April 16th to 18th. We are looking forward to our keynote panel discussion on 'The Disruption of Life Sciences Value Chains – How Leading Companies Transform Their Value Chains for the Next Digital Era' with Nicola Trombach from Bayer, Thierry Harlingue from Roche, Mandar Paralkar from SAP and Patrick Wolf from Tenthpin . We asked Patrick Wolf, Partner at Tenthpin what he's looking forward to most about this event and here's what he had to say - "Excited to moderate our panel discussion with SAP and Tenthpin at LogiPharma during prime time and looking forward to valuable insights into Roche's digitalization efforts in Cell & Gene Therapies from Thierry Harlingue." Join us at 10:20 AM in the plenary as we talk about crucial topics such as: - Patient-Centricity and individual treatments: Impacts on the Life Sciences Value Chain - Collaboration: Flexibility and speed in integrating partners, suppliers, and clients - Data-driven Supply Chains: Leveraging technology in the upcoming era of AI If you're attending LogiPharma and want to explore solutions in the digital transformation of Pharma Value Chains, come talk to us! #LogiPharma2024 #Tenthpin #LifeSciences #ValueChain

In this article, Rolf Turk from Integrated DNA Technologies discusses the future of CRISPR and the opportunity to develop new tools for genomic medicine.

Prenetics Global Limited (NASDAQ: PRE), a genomics-driven health sciences company, is making waves in the industry. With its three primary units – CircleDNA, Insighta, and ACT Genomics – PRE is advancing personalized medicine, early cancer detection, and genomic profiling for personalized cancer treatments. In the first quarter of 2024, PRE reported impressive financial results, including a 30.2% increase in revenue and a 159.8% surge in gross profit compared to the previous year. The company's strategic focus on the US consumer healthcare market aims to broaden accessibility to its science-based solutions. 'The first quarter of 2024 marked a good start for our company, showcasing solid growth in revenue and gross profit. These results demonstrate firm governance of our financial position with no debt, supported by a resilient and talented team,' said Danny Yeung, Chief Executive Officer and Co-Founder of PRE. PRE recently announced a partnership with former international footballer David Beckham, who has become a strategic investor and co-founding partner of a new health and wellness brand, IM8. 'This partnership with David marks a transformative era for PRE in global health innovation and wellness,' Yeung stated. With its innovative approach, strong financial performance, and high-profile collaborations, Prenetics Global Limited is poised to drive significant advancements in genomics and consumer health. #genomics #personalizedmedicine #cancerdetection #healthinnovation

For a therapy to be successful, it must show both clinical impact and commercial adoption. Recent years have seen several therapies removed from the market due to lack of commercial adoption. As the rate of clinical success of these therapies grows, the industry needs to work harder to develop innovative solutions and enable widespread patient access. Sanjay Srivastava, PhD of Accenture and Jason C. Foster talked about the changing landscape of CGT and the challenges that need to be addressed. They discuss a future where: 🌐 Customized medicine becomes more accessible 🔄 Supply chains evolve to support personalized treatments 🔬 Manufacturing adapts to the complexities of living therapies 👥 Collaboration enhances scalability and affordability Overcoming these manufacturing hurdles will ensure advanced therapies can be produced efficiently, making them more accessible to patients in need. Thank you Cell & Gene for featuring Sanjay and Jason: https://lnkd.in/eQxrgCC4 #ManufacturingBrighterFutures #CellTherapy #GeneTherapy #PatientAccess #Biotechnology

Good insights for those working in the CGT space. 

Fierce Biotech's 'Fierce 15' for 2024! • Abdera Therapeutics: Targeting tough-to-treat cancers with versatile #radiopharmaceuticals • Ascidian Therapeutics: Developing exon-editing #RNAtherapeutics with inspiration from sea squirts  • BigHat Biosciences: Using #ML and #syntheticbiology to find better antibodies • Cour Pharmaceuticals Development Co., Inc.: Retraining the culprits at the center of #autoimmunediseases  • Excision BioTherapeutics: Using #CRISPR tech to excise #viral #genomes • Fauna Bio: Examining genes and pathways in other species to identify targets for human medicines • Gilgamesh Pharmaceuticals: Developing novel #psychedelic treatments to target the root causes of #mentaldisorders with fewer side effects • iECURE, inc.: a #biotech from the labs of University of Pennsylvania scientist Jim Wilson, M.D., Ph.D., tackling rare childhood diseases • ILiAD Biotechnologies, LLC: Pioneering new treatments and immunizations against diseases caused by Bordetella Pertussis • Kimer Med: Developing broad-spectrum antiviral #biologics  • NodThera: Targeting inflammation-driven diseases at the source through the NLRP3 inflammasome • OMass Therapeutics: Harnessing native #massspectrometry and custom #chemistry to tackle #immunological and #orphandiseases • ProFound Therapeutics: Protein #drugdiscovery, Shining a light on the proteins hiding in plain sight • Recludix Pharma: Unlocking the potential of SH2 domain-targeted therapies • Tubulis GmbH: Limiting target-independent toxicity in order to make better ADCs Precision BioPartners #biotechnology #biotechnologie #scienceandtechnologies #lifesciences #biopharma #biopharmaceuticals #science #research #researchanddevelopment #healthcare #innovation #therapeutics #startup #startups #promising #technologies #cuttingedgetechnologies #linkedin #pharma #pharmaceuticals #drugdevelopment #lifesciences #biotechnews https://lnkd.in/e6GezH2t

Exciting News! Verge Genomics and Ferrer are collaborating to advance VRG50635, Verge’s lead drug candidate for treating both sporadic and familial forms of #ALS. This partnership, Verge’s third with a major pharma company, underscores the value of the CONVERGE® platform in identifying novel targets for complex diseases. VRG50635 is one of the first candidate drugs to enter the clinic that was entirely discovered and developed using #AI. By combining Verge's all-in-human technology with Ferrer's global expertise in clinical development and commercialization, we aim to make a meaningful impact on those affected by ALS. For more information, read the announcement: https://bit.ly/3PA1ctA #Innovation #AIinhealthcare #DrugDevelopment

𝗕𝗮𝗹𝗮𝗻𝗰𝗶𝗻𝗴 𝗔𝗰𝘁: 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗥𝗲𝗮𝗹-𝗧𝗶𝗺𝗲 𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗶𝗼𝗻 ⚖️ In 2025, regulators might achieve a delicate balance: fostering rapid innovation while maintaining robust, real-time oversight. 𝗞𝗲𝘆 𝗲𝗹𝗲𝗺𝗲𝗻𝘁𝘀: 📊 Increasing use of real-world evidence in decision making 🧬 New approaches for evaluating complex therapies like gene editing 🔄 Adaptive trial designs and innovative endpoints ⚡ Faster approvals for breakthrough therapies 𝗘𝘅𝗽𝗹𝗮𝗶𝗻𝗶𝗻𝗴 𝘁𝗵𝗲 𝗰𝗼𝗻𝗰𝗲𝗽𝘁: This prediction suggests a move away from the traditional, linear approach to drug and device approval. Instead, we're looking at a more flexible, adaptive process that can keep pace with rapid scientific advancements while ensuring patient safety. 𝗪𝗵𝘆 𝘆𝗼𝘂 𝘀𝗵𝗼𝘂𝗹𝗱 𝗰𝗮𝗿𝗲: For life science and quality professionals, this shift could lead to: 🚀 More rapid development cycles for innovative products 📈 Increased importance of post-market surveillance and real-world data 🧪 New opportunities in designing and managing adaptive trials 🔍 Greater need for continuous learning and adaptation in regulatory strategies Are you prepared for a world where regulation moves at the speed of innovation? It's time to start thinking adaptively! 🦋 ************************************************** 📢 For more, follow me here: https://lnkd.in/efHgEZQA 🔔 Ring the bell to ensure you get notified of new posts. ************************************************** #RealTimeRegulation, #AdaptiveTrials, #RegulatoryBalance, #InnovationOversight, #RWEinRegulation